Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat?

L. Kerbiriou; A. Ustianowski; M. A. Johnson; S. H. Gillespie; R. F. Miller; M. C.I. Lipman

doi:10.1086/378806

Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat?

L. Kerbiriou, A. Ustianowski, M. A. Johnson, S. H. Gillespie, R. F. Miller, M. C.I. Lipman^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

We report treatment decisions and outcomes for 20 patients who were infected with human immunodeficiency virus type 1 (HIV-1) and were receiving highly active antiretroviral therapy (HAART) who had respiratory symptoms and from whom Mycobacterium xenopi was isolated. All patients also had coexisting pulmonary pathologic conditions. The median blood T cell CD4 count was 37 cells/μL (range, 2-480 cells/μL). Fifteen of 20 patients received no antimycobacterial therapy and remain healthy after a median of ∼4 years of follow-up, and 2 patients required treatment specifically for M. xenopi infection, both showing clinical improvement. We conclude that pulmonary M. xenopi isolation in HIV-1 patients receiving HAART does not usually require specific treatment.

Original language	English
Pages (from-to)	1250-1254
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	37
Issue number	9
DOIs	https://doi.org/10.1086/378806
Publication status	Published - 1 Nov 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1086/378806

Cite this

@article{54f55616b37f469fb6319980b3b7a1ed,

title = "Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat?",

abstract = "We report treatment decisions and outcomes for 20 patients who were infected with human immunodeficiency virus type 1 (HIV-1) and were receiving highly active antiretroviral therapy (HAART) who had respiratory symptoms and from whom Mycobacterium xenopi was isolated. All patients also had coexisting pulmonary pathologic conditions. The median blood T cell CD4 count was 37 cells/μL (range, 2-480 cells/μL). Fifteen of 20 patients received no antimycobacterial therapy and remain healthy after a median of ∼4 years of follow-up, and 2 patients required treatment specifically for M. xenopi infection, both showing clinical improvement. We conclude that pulmonary M. xenopi isolation in HIV-1 patients receiving HAART does not usually require specific treatment.",

author = "L. Kerbiriou and A. Ustianowski and Johnson, {M. A.} and Gillespie, {S. H.} and Miller, {R. F.} and Lipman, {M. C.I.}",

year = "2003",

month = nov,

day = "1",

doi = "10.1086/378806",

language = "English",

volume = "37",

pages = "1250--1254",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection

T2 - A Need to Treat?

AU - Kerbiriou, L.

AU - Ustianowski, A.

AU - Johnson, M. A.

AU - Gillespie, S. H.

AU - Miller, R. F.

AU - Lipman, M. C.I.

PY - 2003/11/1

Y1 - 2003/11/1

N2 - We report treatment decisions and outcomes for 20 patients who were infected with human immunodeficiency virus type 1 (HIV-1) and were receiving highly active antiretroviral therapy (HAART) who had respiratory symptoms and from whom Mycobacterium xenopi was isolated. All patients also had coexisting pulmonary pathologic conditions. The median blood T cell CD4 count was 37 cells/μL (range, 2-480 cells/μL). Fifteen of 20 patients received no antimycobacterial therapy and remain healthy after a median of ∼4 years of follow-up, and 2 patients required treatment specifically for M. xenopi infection, both showing clinical improvement. We conclude that pulmonary M. xenopi isolation in HIV-1 patients receiving HAART does not usually require specific treatment.

AB - We report treatment decisions and outcomes for 20 patients who were infected with human immunodeficiency virus type 1 (HIV-1) and were receiving highly active antiretroviral therapy (HAART) who had respiratory symptoms and from whom Mycobacterium xenopi was isolated. All patients also had coexisting pulmonary pathologic conditions. The median blood T cell CD4 count was 37 cells/μL (range, 2-480 cells/μL). Fifteen of 20 patients received no antimycobacterial therapy and remain healthy after a median of ∼4 years of follow-up, and 2 patients required treatment specifically for M. xenopi infection, both showing clinical improvement. We conclude that pulmonary M. xenopi isolation in HIV-1 patients receiving HAART does not usually require specific treatment.

UR - http://www.scopus.com/inward/record.url?scp=0242574931&partnerID=8YFLogxK

U2 - 10.1086/378806

DO - 10.1086/378806

M3 - Article

C2 - 14557971

AN - SCOPUS:0242574931

SN - 1058-4838

VL - 37

SP - 1250

EP - 1254

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 9

ER -

Human Immunodeficiency Virus Type 1-Related Pulmonary Mycobacterium xenopi Infection: A Need to Treat?

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this